251 related articles for article (PubMed ID: 27244218)
21. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.
Hino H; Shiomi A; Kusuhara M; Kagawa H; Yamakawa Y; Hatakeyama K; Kawabata T; Oishi T; Urakami K; Nagashima T; Kinugasa Y; Yamaguchi K
Cancer Med; 2019 Aug; 8(10):4587-4597. PubMed ID: 31240875
[TBL] [Abstract][Full Text] [Related]
22. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
23. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
Baldus CD; Thibaut J; Goekbuget N; Stroux A; Schlee C; Mossner M; Burmeister T; Schwartz S; Bloomfield CD; Hoelzer D; Thiel E; Hofmann WK
Haematologica; 2009 Oct; 94(10):1383-90. PubMed ID: 19794083
[TBL] [Abstract][Full Text] [Related]
25. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
26. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor.
Sancho R; Jandke A; Davis H; Diefenbacher ME; Tomlinson I; Behrens A
Gastroenterology; 2010 Sep; 139(3):929-41. PubMed ID: 20638938
[TBL] [Abstract][Full Text] [Related]
27. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
[TBL] [Abstract][Full Text] [Related]
28. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
Jardim DL; Wheler JJ; Hess K; Tsimberidou AM; Zinner R; Janku F; Subbiah V; Naing A; Piha-Paul SA; Westin SN; Roy-Chowdhuri S; Meric-Bernstam F; Hong DS
PLoS One; 2014; 9(2):e89388. PubMed ID: 24586741
[TBL] [Abstract][Full Text] [Related]
29. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
Babaei-Jadidi R; Li N; Saadeddin A; Spencer-Dene B; Jandke A; Muhammad B; Ibrahim EE; Muraleedharan R; Abuzinadah M; Davis H; Lewis A; Watson S; Behrens A; Tomlinson I; Nateri AS
J Exp Med; 2011 Feb; 208(2):295-312. PubMed ID: 21282377
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
Mansour MR; Sulis ML; Duke V; Foroni L; Jenkinson S; Koo K; Allen CG; Gale RE; Buck G; Richards S; Paietta E; Rowe JM; Tallman MS; Goldstone AH; Ferrando AA; Linch DC
J Clin Oncol; 2009 Sep; 27(26):4352-6. PubMed ID: 19635999
[TBL] [Abstract][Full Text] [Related]
31. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
[TBL] [Abstract][Full Text] [Related]
32. Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway.
Wang X; Zhang J; Zhou L; Sun W; Zheng ZG; Lu P; Gao Y; Yang XS; Zhang ZC; Tao KS; Dou KF
Int J Oncol; 2015 Jul; 47(1):231-43. PubMed ID: 25955618
[TBL] [Abstract][Full Text] [Related]
33. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
34. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
Asnafi V; Buzyn A; Le Noir S; Baleydier F; Simon A; Beldjord K; Reman O; Witz F; Fagot T; Tavernier E; Turlure P; Leguay T; Huguet F; Vernant JP; Daniel F; Béné MC; Ifrah N; Thomas X; Dombret H; Macintyre E
Blood; 2009 Apr; 113(17):3918-24. PubMed ID: 19109228
[TBL] [Abstract][Full Text] [Related]
35. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
36. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.
Korphaisarn K; Morris VK; Overman MJ; Fogelman DR; Kee BK; Raghav KPS; Manuel S; Shureiqi I; Wolff RA; Eng C; Menter D; Hamilton SR; Kopetz S; Dasari A
Oncotarget; 2017 Jun; 8(24):39268-39279. PubMed ID: 28424412
[TBL] [Abstract][Full Text] [Related]
37. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
38. hCDC4 gene mutation is rare in colorectal carcinomas in Korean patients.
Lee JW; Jeong EG; Lee SH; Yoo NJ; Lee SH
Pathology; 2008 Apr; 40(3):305. PubMed ID: 18428053
[No Abstract] [Full Text] [Related]
39. The FBXW7 beta-form is suppressed in human glioma cells.
Gu Z; Inomata K; Ishizawa K; Horii A
Biochem Biophys Res Commun; 2007 Mar; 354(4):992-8. PubMed ID: 17274947
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
